• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Evaxion A/S

    8/14/25 7:30:17 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EVAX alert in real time by email
    evax20250814_6k.htm
    0001828253 June 30, 2025 false --12-31 Q2 2025
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


     

    FORM 6-K

     


     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO SECTION 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of August 2025

     

    Commission File Number: 001-39950

     


     

    Evaxion Biotech A/S

    (Exact Name of Registrant as Specified in Its Charter)

     


     

    Dr. Neergaards Vej 5f

    DK-2970 Hoersholm

    Denmark

    (Address of principal executive offices)

     


     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒               Form 40-F ☐

     

     

     

     

    INCORPORATION BY REFERENCE

     

    Exhibits 99.1 and 99.2 of this report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132) and on Form F-1 (File No. 333-266050), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Furnished as Exhibits to this Report on Form 6-K is information regarding the Company’s financial results for the fiscal quarter ended June 30, 2025.

     

     

     

     

     

     

     

     

    Exhibits

     

    Exhibit

       

    No.

     

    Description

    99.1

     

    Unaudited Condensed Consolidated Interim Financial Statements.

    99.2

     

    Management’s Discussion and Analysis of Financial Condition and Results of Operations.

    101.INS

     

    Inline XBRL Instance Document

    101.SCH

     

    Inline XBRL Taxonomy Extension Schema

    101.CAL

     

    Inline XBRL Taxonomy Extension Calculation Linkbase

    101.DEF

     

    Inline XBRL Taxonomy Extension Definition Linkbase

    101.LAB

     

    Inline XBRL Taxonomy Extension Label Linkbase

    101.PRE

     

    Inline XBRL Taxonomy Extension Presentation Linkbase

    104

     

    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

     

     

     

     

     

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Evaxion Biotech A/S

         

    Date: August 13, 2025

    By:

    /s/ Birgitte Rønø

       

    Birgitte Rønø

       

    Chief Executive Officer

     

         
         

    Date: August 13, 2025

    By:

    /s/ Thomas Frederik Schmidt

       

    Thomas Frederik Schmidt

       

    Chief Financial Officer

     

     
    Get the next $EVAX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVAX

    DatePrice TargetRatingAnalyst
    4/2/2024$8.00Neutral → Buy
    Ladenburg Thalmann
    2/12/2024$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $EVAX
    SEC Filings

    View All

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    10/8/25 8:05:44 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    10/6/25 6:03:38 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    9/25/25 7:15:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evaxion expands AI-Immunology™ platform with automated vaccine design module

    New platform module automates previous manual vaccine design processes, improving quality and dramatically reducing time and resource requirementsAI-Immunology™, already superior in vaccine target discovery, now also enables enhanced design applicable for both new vaccines and optimization of approved onesEvaxion will present detailed validation data on these improvements at the World Vaccine Congress Europe in Amsterdam on October 15, 2025 COPENHAGEN, Denmark, October 8, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is launching a significant improvement of its already leading AI-platform, AI-Imm

    10/8/25 8:12:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

    New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting The data will be the latest of many additions to EVX-01's strong data packageTwo-year clinical efficacy data from the trial will be presented at the European Society for Medical Oncology (ESMO) 2025 congress on October 17, 2025 COPENHAGEN, Denmark, October 3, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present new data for its lead asset EVX-01 at a poster session at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting

    10/3/25 9:00:38 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion out-licenses vaccine candidate EVX-B3 to MSD

    MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion's cash runway to first half of 2027 MSD will assume full responsibility for the further development of EVX-B3 with Evaxion eligible for development, regulatory and sales milestone payments with a potential value of up to $592 million, as well as royalties on salesMSD retains an option for a second vaccine candidate, EVX-B2, for which the evaluation period is extended with a decision on potential licensing expected in the first half of 2026Evaxion will host a conference call and webcast to discuss these events at 2.30pm CT/8.30am ET today COPENHAGEN, Denmark, September 25, 2025 - Eva

    9/25/25 7:00:57 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evaxion Biotech upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded Evaxion Biotech from Neutral to Buy and set a new price target of $8.00

    4/2/24 11:31:47 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Evaxion Biotech with a new price target

    H.C. Wainwright initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $14.00

    2/12/24 6:37:53 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Evaxion Biotech A/S with a new price target

    Oppenheimer initiated coverage of Evaxion Biotech A/S with a rating of Outperform and set a new price target of $18.00

    3/8/21 8:22:12 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer

    Dr. Rønø has developed Evaxion's pre-clinical and early clinical oncology pipelineNewly-created Chief Scientific Officer role strengthens Evaxion's leadership team COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has promoted its Senior Director, Immuno-Oncology, Birgitte Rønø, Ph.D, to the newly-created position of Chief Scientific Officer, effective immediately. Lars Wegner, CEO of Evaxion, said: "As Senior Di

    9/21/21 8:34:52 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion Biotech Appoints Lars Holtug to the Board of Directors

    COPENHAGEN, Denmark, May 26, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today its shareholders elected Lars Holtug, a highly experienced financial professional with specific expertise in the healthcare industry, as a member of its Board of Directors. The vote was held at Evaxion's Annual General Meeting on May 25, 2021. Lars Holtug will also chair Evaxion's Audit Committee, taking over from Helen M. Boudreau, who chose not to stand for re-election for personal reasons. Marianne Søgaard, Chairwo

    5/26/21 8:30:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Financials

    Live finance-specific insights

    View All

    Evaxion out-licenses vaccine candidate EVX-B3 to MSD

    MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion's cash runway to first half of 2027 MSD will assume full responsibility for the further development of EVX-B3 with Evaxion eligible for development, regulatory and sales milestone payments with a potential value of up to $592 million, as well as royalties on salesMSD retains an option for a second vaccine candidate, EVX-B2, for which the evaluation period is extended with a decision on potential licensing expected in the first half of 2026Evaxion will host a conference call and webcast to discuss these events at 2.30pm CT/8.30am ET today COPENHAGEN, Denmark, September 25, 2025 - Eva

    9/25/25 7:00:57 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

    COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 14, 2025, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone

    8/11/25 8:00:43 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

    COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 financial results on Tuesday, May 27, 2025, before opening of the Nasdaq CM.Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers an

    5/23/25 8:00:51 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Evaxion Biotech A/S

    SC 13G - Evaxion Biotech A/S (0001828253) (Subject)

    11/14/24 3:29:53 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evaxion Biotech A/S

    SC 13G/A - Evaxion Biotech A/S (0001828253) (Subject)

    11/6/24 4:09:57 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Evaxion Biotech A/S

    SC 13G - Evaxion Biotech A/S (0001828253) (Subject)

    1/23/24 3:29:11 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care